Compounds > cannabidiolic acid
Page last updated: 2024-09-26

cannabidiolic acid

Description

cannabidiolic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cannabidiolic acid : A dihydroxybenzoic acid that is olivetolic acid in which the hydrogen at position 3 is substituted by a 3-p-mentha-1,8-dien-3-yl (limonene) group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID160570
CHEMBL ID498672
CHEBI ID3359
SCHEMBL ID141666
MeSH IDM0049703

Synonyms (32)

Synonym
1244-58-2
cannabidiolic acid
cbda
3-p-mentha-1,8-dien-3-yl-6-pentyl-beta-resorcylic acid
LMPK13120003
2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-6-pentylbenzoic acid
cannabidiol acid
chebi:3359 ,
CHEMBL498672 ,
bdbm50318485
2,4-dihydroxy-3-((1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-enyl)-6-pentylbenzoic acid
2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid
fjx8o3ojcd ,
unii-fjx8o3ojcd
SCHEMBL141666
cannabidiolic acid [nflis-drug]
benzoic acid, 2,4-dihydroxy-3-((1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-6-pentyl-
cannabidiolcarboxylic acid
DTXSID80154318 ,
WVOLTBSCXRRQFR-DLBZAZTESA-N
Q27106043
benzoic acid, 2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-6-pentyl-
cannabidiolic acid (cbda)
cannabidiolic acid (cbda) 100 microg/ml in acetonitrile
cannabidiolic acid (cbda) 1000 microg/ml in acetonitrile
gtpl10600
cannabidiolic acid (cbda) 250 microg/ml in acetonitrile
FS-10258
dtxcid8076809
cannabidiolic acid (nflis-drug)
2,4-dihydroxy-3-((1r,6r)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl)-6-pentylbenzoic acid
cannabidiolic acid (cbda), 1mg/ml in acetonitrile

Actions

ExcerptReference
"Cannabidiolic acid (CBDA) can activate peroxisome proliferator-activated receptor-α (PPARα) and PPARγ. "( Hirao-Suzuki, M; Peters, JM; Takayuki, K; Takeda, S; Takiguchi, M, 2022)

Drug Classes (4)

ClassDescription
phytocannabinoidA class of cannabinoid which are C21 terpenophenolic compounds isolated primarily from Cannabis sativa.
resorcinolsAny benzenediol in which the two hydroxy groups are meta to one another.
polyketideNatural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides.
dihydroxybenzoic acidAny member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

cannabidiolic acid is involved in 1 pathway(s), involving a total of 0 unique proteins and 8 unique compounds

PathwayProteinsCompounds
CBD synthetic pathway08

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
N-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)IC50 (µMol)23.00000.70000.70000.7000AID1625159
Diacylglycerol lipase-alphaHomo sapiens (human)IC50 (µMol)19.40000.00101.05385.0119AID1625150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Rattus norvegicus (Norway rat)EC50 (µMol)12.00000.06002.22238.4000AID482146
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
fatty acid metabolic processN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
sphingosine metabolic processN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
lipid catabolic processN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
N-acylethanolamine metabolic processN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
N-acylphosphatidylethanolamine metabolic processN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
monoacylglycerol biosynthetic processDiacylglycerol lipase-alphaHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayDiacylglycerol lipase-alphaHomo sapiens (human)
neuroblast proliferationDiacylglycerol lipase-alphaHomo sapiens (human)
arachidonic acid metabolic processDiacylglycerol lipase-alphaHomo sapiens (human)
diacylglycerol catabolic processDiacylglycerol lipase-alphaHomo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidDiacylglycerol lipase-alphaHomo sapiens (human)
regulation of neuroinflammatory responseDiacylglycerol lipase-alphaHomo sapiens (human)
cannabinoid biosynthetic processDiacylglycerol lipase-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
hydrolase activity, acting on carbon-nitrogen (but not peptide) bondsN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
N-acylsphingosine amidohydrolase activityN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
fatty acid amide hydrolase activityN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
N-(long-chain-acyl)ethanolamine deacylase activityN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
ceramidase activityN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
DNA-binding transcription factor bindingN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
protein bindingDiacylglycerol lipase-alphaHomo sapiens (human)
metal ion bindingDiacylglycerol lipase-alphaHomo sapiens (human)
acylglycerol lipase activityDiacylglycerol lipase-alphaHomo sapiens (human)
lipoprotein lipase activityDiacylglycerol lipase-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
cytoplasmN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
lysosomeN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
membraneN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
lysosomal lumenN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
extracellular exosomeN-acylethanolamine-hydrolyzing acid amidaseHomo sapiens (human)
plasma membraneDiacylglycerol lipase-alphaHomo sapiens (human)
early endosome membraneDiacylglycerol lipase-alphaHomo sapiens (human)
dendrite membraneDiacylglycerol lipase-alphaHomo sapiens (human)
dendritic spine membraneDiacylglycerol lipase-alphaHomo sapiens (human)
varicosityDiacylglycerol lipase-alphaHomo sapiens (human)
postsynaptic density membraneDiacylglycerol lipase-alphaHomo sapiens (human)
dendrite membraneDiacylglycerol lipase-alphaHomo sapiens (human)
cytoplasmDiacylglycerol lipase-alphaHomo sapiens (human)
postsynaptic membraneDiacylglycerol lipase-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID1617287Ratio of drug level in anesthetized C57BL/6J mouse brain to plasma at 5 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617295AUC in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1625160Inhibition of recombinant human NAAA expressed in HEK293 cells at 100 uM using [14C]-N-palmitoylethanolamine as substrate measured after 30 mins by beta-counting method relative to control2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1617279Cmax in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617293Half life in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID362544Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 25923 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1617304Partition coefficient, log P of compound2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1825221Cytotoxicity against African green monkey Vero E6 cells by resazurin assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1825218Antiviral activity against SARS-CoV-2 isolate USA-WA1/2020 strain infected in African green monkey Vero E6 cells assessed as inhibition of viral entry incubated for 1 hr prior to infection and measured after 48 hrs by Focus forming assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1617275Half life in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617278AUC in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1782665Inhibition of human LDHB assessed as reduction in lactate production using pyruvate as substrate at 10 uM in presence of NADH by spectrophotometric analysis relative to control2021Journal of natural products, 05-28, Volume: 84, Issue:5
Cannabichromene and Δ
AID1825222Cytotoxicity against human Caco-2 cells by resazurin assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1625150Inhibition of recombinant human DAGLalpha expressed in COS7 cells using [14C]-oleoyl-2-arachidonoyl-glycerol as substrate measured after 20 mins by beta-counting method2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1625159Inhibition of recombinant human NAAA expressed in HEK293 cells using [14C]-N-palmitoylethanolamine as substrate measured after 30 mins by beta-counting method2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1625156Inhibition of FAAH in rat brain membranes using [14C]-AEA as substrate measured after 30 mins by scintillation counting method2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1617276Half life in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617274Tmax in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617300Drug metabolism in brain of anesthetized C57BL/6J mouse at 10 mg/kg, ip by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617307Anticonvulsant activity against hyperthermia-induced seizure in Scn1aRX/+ mouse model of Dravet syndrome assessed as increase in generalized tonic-clonic seizure temperature threshold at 10 to 30 mg/kg, ip administered as single dose measured by RET-3 rec2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1625155Inhibition of MAGL in African green monkey COS cell homogenates at 50 uM using [3H]-arachidonoylglycerol as substrate measured after 20 mins by scintillation counting method relative to control2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID362541Antibacterial activity against methicillin-resistant Staphylococcus aureus SA1199B after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1625151Inhibition of recombinant human DAGLalpha expressed in COS7 cells at 50 uM using [14C]-oleoyl-2-arachidonoyl-glycerol as substrate measured after 20 mins by beta-counting method relative to control2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1617291Tmax in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617288Ratio of drug level in anesthetized C57BL/6J mouse brain to plasma at 5 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617271Cmax in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617281Tmax in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617284Half life in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1625157Inhibition of FAAH in rat brain membranes at 50 uM using [14C]-AEA as substrate measured after 30 mins by scintillation counting method relative to control2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1617273Tmax in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617286AUC in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1625163Inhibition of [14C]-AEA uptake in rat RBL2H3 cells at 25 uM by scintillation counting method relative to control2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1825216Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral entry at 25 ug/ml measured after 24 hrs post infection by fluorescence microscopy2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID362542Antibacterial activity against macrolide-resistant Staphylococcus aureus RN4220 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID362545Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 15 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1625153Inhibition of MAGL in African green monkey COS cell homogenates using [3H]-arachidonoylglycerol as substrate measured after 20 mins by scintillation counting method2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID482146Agonist activity at rat TRPA1 channel expressed in HEK293 cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1617283Half life in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617272Cmax in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617292Tmax in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617294Half life in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617280Cmax in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1825217Antiviral activity against pseudovirus SARS-CoV-2 spike protein infected in HEK293T cells overexpressing ACE2 assessed as inhibition on pseudovirus infection incubated for 45 hrs by fluorescence microscopy2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1617282Tmax in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617277AUC in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617270Ratio of drug level in anesthetized C57BL/6J mouse brain to plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID362543Antibacterial activity against tetracycline-resistant Staphylococcus aureus XU212 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID362546Antibacterial activity against epidemic methicillin-resistant Staphylococcus aureus 16 after 18 hrs2008Journal of natural products, Aug, Volume: 71, Issue:8
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.
AID1825219Antiviral activity against SARS-CoV-2 variant B.1.1.7 strain infected in African green monkey Vero E6 cells assessed as inhibition of viral entry incubated for 1 hr proir to infection and measured after 48 hrs by Focus forming assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1825223Cytotoxicity against human HEK293T cells overexpressing ACE2 by resazurin assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1617303Dissociation constant, pKa of compound2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617285AUC in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of vegetable oil by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617299Drug uptake in plasma of anesthetized C57BL/6J mouse at 10 mg/kg, ip by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617296AUC in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1825220Antiviral activity against SARS-CoV-2 variant B.1.351 strain infected in African green monkey Vero E6 cells assessed as inhibition of viral entry incubated for 1 hr prior to infection and measured after 48 hrs by Focus forming assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants.
AID1625162Inhibition of [14C]-AEA uptake in rat RBL2H3 cells by scintillation counting method2019Journal of natural products, 03-22, Volume: 82, Issue:3
Plant-Based Modulators of Endocannabinoid Signaling.
AID1617290Cmax in anesthetized C57BL/6J mouse brain at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
AID1617289Cmax in anesthetized C57BL/6J mouse plasma at 10 mg/kg, ip administered as single dose measured upto 240 mins in presence of tween-80 by LC-MS/MS analysis2019Journal of natural products, 11-22, Volume: 82, Issue:11
Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.32)18.7374
1990's1 (1.32)18.2507
2000's5 (6.58)29.6817
2010's32 (42.11)24.3611
2020's37 (48.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.32%)5.53%
Reviews6 (7.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other69 (90.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
cannabinol[no description available]medium50dibenzopyran
norfloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
resorcinol[no description available]medium10benzenediol;
phenolic donor;
resorcinols		erythropoietin inhibitor;
sensitiser
oxacillin[no description available]medium10penicillinantibacterial agent;
antibacterial drug
olivetol[no description available]medium10resorcinolslichen metabolite
erythromycin[no description available]medium10cyclic ketone;
erythromycin
dronabinol[no description available]medium310benzochromene;
diterpenoid;
phytocannabinoid;
polyketide		cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic
cannabichromene[no description available]medium401-benzopyran
abnormal cannabidiol[no description available]medium10monoterpenoid
delta(9)-tetrahydrocannabinolic acid[no description available]medium80benzochromene;
diterpenoid;
hydroxy monocarboxylic acid;
phytocannabinoid;
polyketide		anti-inflammatory agent;
biomarker;
metabolite;
neuroprotective agent
cannabidiol-3-monomethyl ether[no description available]medium10
cannabidiol[no description available]medium270olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
cannabidiol[no description available]medium271olefinic compound;
phytocannabinoid;
resorcinols		antimicrobial agent;
plant metabolite
cannabidiol dimethyl ether[no description available]medium20
cannabigerol[no description available]medium50phytocannabinoid;
resorcinols		anti-inflammatory agent;
antibacterial agent;
antioxidant;
appetite enhancer;
cannabinoid receptor agonist;
neuroprotective agent;
plant metabolite
cannabigerolic acid[no description available]medium90dihydroxybenzoic acid;
diterpenoid;
phytocannabinoid;
polyketide;
resorcinols
tetracycline[no description available]medium10
menthol[no description available]medium10p-menthane monoterpenoid;
secondary alcohol		volatile oil component
bay-k-8644[no description available]medium10(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
benzyl isothiocyanate[no description available]medium10benzenes;
isothiocyanate		antibacterial drug
disulfiram[no description available]medium10organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
nicardipine[no description available]medium10benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
nifedipine[no description available]medium10C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nimodipine[no description available]medium102-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nitrendipine[no description available]medium10C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
allyl isothiocyanate[no description available]medium10alkenyl isothiocyanate;
isothiocyanate		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lachrymator;
metabolite
thymol[no description available]medium10monoterpenoid;
phenols		volatile oil component
benzyl bromide[no description available]medium10benzyl bromideslachrymator
ethyl bromoacetate[no description available]medium10
acrolein[no description available]medium10enalherbicide;
human xenobiotic metabolite;
toxin
dibenz(b,f)(1,4)oxazepine[no description available]medium10
carvacrol[no description available]medium10botanical anti-fungal agent;
p-menthane monoterpenoid;
phenols		agrochemical;
antimicrobial agent;
flavouring agent;
TRPA1 channel agonist;
volatile oil component
toluene 2,4-diisocyanate[no description available]medium10toluene meta-diisocyanateallergen;
hapten
allyl sulfide[no description available]medium10organic sulfide
bromoacetone[no description available]medium10alpha-bromoketonelachrymator
diallyl trisulfide[no description available]medium10organic trisulfideanti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
antioxidant;
antiprotozoal drug;
apoptosis inducer;
estrogen receptor antagonist;
insecticide;
platelet aggregation inhibitor;
vasodilator agent
perillaldehyde[no description available]medium10aldehyde;
olefinic compound		human metabolite;
mouse metabolite;
volatile oil component
diallyl disulfide[no description available]medium10organic disulfideantifungal agent;
antineoplastic agent;
plant metabolite
phenethyl isothiocyanate[no description available]medium10isothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
chlordantoin[no description available]medium10imidazolidine-2,4-dione
isovelleral[no description available]medium10aldehyde
allicin[no description available]medium10botanical anti-fungal agent;
sulfoxide		antibacterial agent
perilla ketone[no description available]medium10aromatic ketone
polygodial[no description available]medium10aldehyde
nicotine[no description available]medium103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
camphora[no description available]medium10camphor
ag 3-5[no description available]medium10C-nitro compound
2-butenal[no description available]medium10enal
cinnamaldehyde[no description available]medium103-phenylprop-2-enal;
cinnamaldehydes		antifungal agent;
EC 4.3.1.24 (phenylalanine ammonia-lyase) inhibitor;
flavouring agent;
hypoglycemic agent;
plant metabolite;
sensitiser;
vasodilator agent
hc 030031[no description available]medium10
urb 597[no description available]medium10biphenyls
prostaglandin a2[no description available]medium10prostaglandins Ahuman metabolite
prostaglandin a1[no description available]medium10prostaglandins A
4-hydroxy-2-nonenal[no description available]medium104-hydroxynon-2-enal;
4-hydroxynonenal
15-deoxy-delta(12,14)-prostaglandin j2[no description available]medium10prostaglandins Jelectrophilic reagent;
insulin-sensitizing drug;
metabolite
farnesylthioacetic acid[no description available]medium10
2-pentenal[no description available]medium102-pentenalplant metabolite
s-trans,trans-farnesylthiosalicylic acid[no description available]medium10sesquiterpenoid
4-oxo-2-nonenal[no description available]medium10enal;
enone		human metabolite
bay-k-8644, (-)-isomer[no description available]medium10(trifluoromethyl)benzenes;
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
bay-k-8644[no description available]medium10(trifluoromethyl)benzenes;
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime[no description available]medium10
8-iso-prostaglandin a2[no description available]medium10prostanoid
miogadial[no description available]medium10
epigallocatechin gallate[no description available]medium10flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
gallocatechol[no description available]medium10catechin;
flavan-3,3',4',5,5',7-hexol		antioxidant;
food component;
plant metabolite
(6ar-trans)-isomer of tetrahydrocannabivarin 9[no description available]medium20
epicatechin gallate[no description available]medium10catechin;
gallate ester;
polyphenol		EC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
metabolite
guineensine[no description available]medium10benzodioxoles
(2E,4E)-N-isobutyl-2,4-dodecadienamide[no description available]medium10fatty amidemetabolite
cannabidivarin[no description available]medium20monoterpenoid
cannabinolic acid[no description available]medium10
methamphetamine[no description available]medium10amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
gw 501516[no description available]medium101,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound		carcinogenic agent;
PPARbeta/delta agonist
thiophenes[no description available]medium10mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
gsk0660[no description available]medium10sulfonamide
lithium chloride[no description available]medium70inorganic chloride;
lithium salt		antimanic drug;
geroprotector
tocopherols[no description available]medium10
myrcene[no description available]medium10monoterpeneanabolic agent;
anti-inflammatory agent;
flavouring agent;
fragrance;
plant metabolite;
volatile oil component
alkenes[no description available]medium10
hexanoyl-coenzyme a[no description available]medium10medium-chain fatty acyl-CoAEscherichia coli metabolite;
human metabolite;
mouse metabolite
olivetolic acid[no description available]medium10benzoic acids;
monocarboxylic acid;
polyketide;
resorcinols		metabolite
galactose[no description available]medium10D-galactose;
galactopyranose		Escherichia coli metabolite;
mouse metabolite
geranyl pyrophosphate[no description available]medium10polyprenyl diphosphateEscherichia coli metabolite;
mouse metabolite
mevalonic acid[no description available]medium103,5-dihydroxy-3-methylpentanoic acid
salicylates[no description available]medium10monohydroxybenzoateplant metabolite
ondansetron[no description available]medium20carbazoles
metoclopramide[no description available]medium10benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound		antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic
chlordiazepoxide[no description available]medium10benzodiazepine
saccharin[no description available]medium101,2-benzisothiazole;
N-sulfonylcarboxamide		environmental contaminant;
sweetening agent;
xenobiotic
asparagine[no description available]medium10amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
glutamic acid[no description available]medium10glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
androstenedione[no description available]medium1017-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
durapatite[no description available]medium10
11-hydroxy-delta(9)-tetrahydrocannabinol[no description available]low00phytocannabinoidhuman xenobiotic metabolite
berotek[no description available]low00resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
hexylresorcinol[no description available]low00resorcinols
metaproterenol[no description available]low00aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound
resveratrol[no description available]low00polyphenol;
resorcinols;
stilbenol		antioxidant;
geroprotector;
glioma-associated oncogene inhibitor;
phytoalexin
terbutaline[no description available]low00phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
resacetophenone[no description available]low00dihydroxyacetophenone;
resorcinols		plant metabolite
alpha-resorcylic acid[no description available]low00dihydroxybenzoic acid;
resorcinols		metabolite
pyoluteorin[no description available]low00aromatic ketone;
beta-hydroxy ketone;
diol;
organochlorine compound;
organochlorine pesticide;
polyketide;
pyrroles;
resorcinols		antibacterial agent;
antifungal agent;
apoptosis inducer;
bacterial metabolite;
marine metabolite
orsellinic acid[no description available]low00dihydroxybenzoic acid;
resorcinols		fungal metabolite;
marine metabolite;
metabolite
5-methoxyresorcinol[no description available]low00monomethoxybenzene;
resorcinols		Brassica napus metabolite
Zearalanone[no description available]low00macrolide;
resorcinols
1-((3,5-dichloro)-2,6-dihydroxy-4-methoxyphenyl)-1-hexanone[no description available]low00dichlorobenzene;
differentiation-inducing factor;
monomethoxybenzene;
resorcinols		eukaryotic metabolite;
signalling molecule
1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl-)-1-pentanone[no description available]low00dichlorobenzene;
differentiation-inducing factor;
monomethoxybenzene;
resorcinols		eukaryotic metabolite;
signalling molecule
2,4,6-triiodoresorcinol[no description available]low00resorcinols
stemphol[no description available]low00resorcinols
4-n-butylresorcinol[no description available]low00resorcinols
dihydropinosylvin[no description available]low00diphenylethane;
resorcinols		EC 1.14.18.1 (tyrosinase) inhibitor;
plant metabolite
knipholone[no description available]low00aromatic ketone;
dihydroxyanthraquinone;
methoxybenzenes;
methyl ketone;
polyphenol;
resorcinols		antineoplastic agent;
antioxidant;
antiplasmodial drug;
leukotriene antagonist;
metabolite
3,5-dihydroxyphenylglycine[no description available]low00amino acid zwitterion;
non-proteinogenic L-alpha-amino acid;
resorcinols
gancaonin I[no description available]low001-benzofurans;
aromatic ether;
resorcinols		antibacterial agent;
plant metabolite
licocoumarone[no description available]low001-benzofurans;
aromatic ether;
resorcinols		antibacterial agent;
apoptosis inducer;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
vedelianin[no description available]low00cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid		antineoplastic agent;
plant metabolite
3,3',4,5'-tetrahydroxystilbene[no description available]low00catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
cct018159[no description available]low00benzodioxine;
pyrazoles;
resorcinols		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
ver-49009[no description available]low00aromatic amide;
monochlorobenzenes;
monomethoxybenzene;
pyrazoles;
resorcinols		Hsp90 inhibitor
zearalenone[no description available]low00macrolide;
resorcinols		fungal metabolite;
mycoestrogen
kuwanon g[no description available]low00resorcinols;
tetrahydroxyflavone		anti-inflammatory agent;
plant metabolite
kuwanon h[no description available]low00resorcinols;
tetrahydroxyflavone		plant metabolite
glycycoumarin[no description available]low00aromatic ether;
coumarins;
resorcinols		antispasmodic drug;
plant metabolite
isosalipurposide[no description available]low00beta-D-glucoside;
chalcones;
monosaccharide derivative;
resorcinols		antioxidant;
plant metabolite
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside[no description available]low00beta-D-glucoside;
resorcinols;
stilbenoid		anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor
noreugenin[no description available]low00chromones;
resorcinols		plant metabolite
ascofuranone[no description available]low00dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid;
tetrahydrofuranone		angiogenesis inhibitor;
antilipemic drug;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite
LL-Z1640-1[no description available]low00macrolide;
resorcinols		metabolite
2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone[no description available]low00chalcones;
monomethoxybenzene;
resorcinols		EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
plant metabolite
ascochlorin[no description available]low00cyclohexanones;
dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid		angiogenesis inhibitor;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite
at 13387[no description available]low00benzamides;
isoindoles;
N-alkylpiperazine;
resorcinols;
tertiary carboxamide		antineoplastic agent;
Hsp90 inhibitor
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one[no description available]low00alkaloid;
chromones;
hydroxypiperidine;
resorcinols;
tertiary amino compound		anti-inflammatory agent;
anti-ulcer drug;
anticholesteremic drug;
antileishmanial agent;
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
fungal metabolite;
plant metabolite
4-methyl-5-pentylbenzene-1,3-diol[no description available]low00resorcinolsantineoplastic agent
schweinfurthin g[no description available]low00cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid		antineoplastic agent;
metabolite
violaceol II[no description available]low00aromatic ether;
catechols;
resorcinols		mycotoxin
schweinfurthin f[no description available]low00cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid		metabolite
3,5-dimethylorsellinic acid[no description available]low00dihydroxybenzoic acid;
resorcinols		Aspergillus metabolite
brartemicin[no description available]low00benzoate ester;
glycosyl glycoside derivative;
resorcinols		antimicrobial agent;
metabolite
ver 52296[no description available]low00aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols		angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
visnagin[no description available]low00aromatic ether;
furanochromone;
polyketide		anti-inflammatory agent;
antihypertensive agent;
EC 1.1.1.37 (malate dehydrogenase) inhibitor;
phytotoxin;
plant metabolite;
vasodilator agent
norsolorinic acid[no description available]low00polyketide;
tetrahydroxyanthraquinone		fungal metabolite
lovastatin[no description available]low00delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
mevastatin[no description available]low002-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
l 154819[no description available]low00carbobicyclic compound;
dihydroxy monocarboxylic acid;
fatty acid ester;
polyketide		Aspergillus metabolite;
drug metabolite;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
teratogenic agent
rubrofusarin[no description available]low00aromatic ether;
benzochromenone;
phenols;
polyketide		biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
fungal metabolite
uvaretin[no description available]low00aromatic ether;
dihydrochalcones;
polyketide;
resorcinol		antineoplastic agent;
plant metabolite
annomontacin[no description available]low00polyketide
aclacinomycin[no description available]low00aminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion		antimicrobial agent;
antineoplastic agent;
metabolite
ml 236a[no description available]low002-pyranones;
carbobicyclic compound;
hexahydronaphthalenes;
polyketide;
secondary alcohol		antiatherosclerotic agent;
anticholesteremic drug;
antilipemic drug;
antimicrobial agent;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
fungal metabolite
rubrofusarin B[no description available]low00aromatic ether;
benzochromenone;
naphtho-gamma-pyrone;
phenols;
polyketide		Aspergillus metabolite
troleandomycin[no description available]low00acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative		EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic
squamocin[no description available]low00polyketide
cefadroxil[no description available]low00polyketide
aclarubicin[no description available]low00aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
averufin[no description available]low00cyclic ketal;
organic heteropentacyclic compound;
polyketide;
polyphenol		fungal metabolite
salinomycin[no description available]low00polyketide;
spiroketal		animal growth promotant;
potassium ionophore
mucocin[no description available]low00polyketide
pederin[no description available]low00cyclic ketal;
diol;
oxanes;
polyketide;
secondary alcohol;
secondary carboxamide		antimitotic;
antineoplastic agent;
bacterial metabolite;
vesicant
benanomicin b[no description available]low00aromatic ether;
disaccharide derivative;
L-alanine derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol
pradimicin b[no description available]low00aromatic ether;
L-alanine derivative;
monosaccharide derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol
manumycin[no description available]low00enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol		antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite
squalestatin 1[no description available]low00acetate ester;
cyclic ketal;
oxabicycloalkane;
polyketide;
tertiary alcohol;
tricarboxylic acid		EC 2.5.1.21 (squalene synthase) inhibitor;
fungal metabolite
asukamycin[no description available]low00enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
fostriecin[no description available]low002-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor
monacolin j[no description available]low002-pyranones;
carbobicyclic compound;
hexahydronaphthalenes;
polyketide;
secondary alcohol		antimicrobial agent;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
fungal metabolite
hypothemycin[no description available]low00aromatic ether;
diol;
enone;
epoxide;
macrolide;
phenols;
polyketide;
secondary alpha-hydroxy ketone		antifungal agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite
fr 900848[no description available]low00cyclopropanes;
nucleoside analogue;
olefinic compound;
polyketide;
secondary carboxamide		antifungal agent;
bacterial metabolite
trilobacin[no description available]low00butenolide;
polyketide;
triol		antineoplastic agent;
plant metabolite
aspalathin[no description available]low00C-glycosyl compound;
catechols;
dihydrochalcones;
polyketide;
polyphenol		antioxidant;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
hypoglycemic agent;
plant metabolite
murisolin[no description available]low00polyketide
zaragozic acid c[no description available]low00acetate ester;
cyclic ketal;
oxabicycloalkane;
polyketide;
tertiary alcohol;
tricarboxylic acid		EC 2.5.1.21 (squalene synthase) inhibitor;
fungal metabolite
monascin[no description available]low00alpha,beta-unsaturated ketone;
gamma-lactone;
organic heterotricyclic compound;
polyketide		antilipemic drug;
antineoplastic agent;
fungal metabolite;
PPARgamma agonist
monascorubrin[no description available]low00azaphilone;
enone;
gamma-lactone;
polyketide;
triketone		anti-inflammatory agent;
antineoplastic agent;
biological pigment;
food colouring;
fungal metabolite;
Hsp90 inhibitor
monacolin l[no description available]low002-pyranones;
hexahydronaphthalenes;
polyketide;
secondary alcohol		anticholesteremic drug;
Aspergillus metabolite;
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor
depudecin[no description available]low00polyketideEC 3.5.1.98 (histone deacetylase) inhibitor;
fungal metabolite
6-[(3E,5E,7S)-5,7-dimethyl-2-oxonona-3,5-dienyl]-2,4-dihydroxy-3-methylbenzaldehyde[no description available]low00dihydroxybenzaldehyde;
polyketide
bacillaene[no description available]low00enamine;
monocarboxylic acid amide;
polyene antibiotic;
polyketide;
secondary alcohol		antibacterial agent;
antimicrobial agent;
bacterial metabolite
asperfuranone[no description available]low002-benzofurans;
cyclic ketone;
diol;
polyketide;
secondary alcohol;
tertiary alcohol;
tertiary alpha-hydroxy ketone		antineoplastic agent;
fungal metabolite
colibactin[no description available]low001,3-thiazoles;
azaspiro compound;
polyketide;
pyrroline;
secondary carboxamide		alkylating agent;
carcinogenic agent;
Escherichia coli metabolite;
genotoxin
2,3-dihydroxybenzoic acid[no description available]low00dihydroxybenzoic acidhuman xenobiotic metabolite;
plant metabolite
protocatechuic acid[no description available]low00catechols;
dihydroxybenzoic acid		antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite
2,5-dihydroxybenzoic acid[no description available]low00dihydroxybenzoic acidEC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
fungal metabolite;
human metabolite;
MALDI matrix material;
mouse metabolite
gamma-resorcylic acid[no description available]low00dihydroxybenzoic acidmetabolite
platensimycin[no description available]low00aromatic amide;
cyclic ether;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor
platencin[no description available]low00aromatic amide;
cyclic ketone;
dihydroxybenzoic acid;
monocarboxylic acid amide;
polycyclic cage		antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
2019 Novel Coronavirus Disease0low20
2019 Novel Coronavirus Infection0low20
2019-nCoV Disease0low20
2019-nCoV Infection0low20
Absence Seizure0low20
Absence Seizures0low20
Ache0low30
Acute Confusional Senile Dementia0low10
Adenocarcinoma0low10
Adenocarcinoma, Basal Cell0low10
Adenocarcinoma, Granular Cell0low10
Adenocarcinoma, Oxyphilic0low10
Adenocarcinoma, Tubular0low10
Adenoma, Malignant0low10
Age-Related Memory Disorders0low10
Air Sickness0low10
Airflow Obstruction, Chronic0low10
Airsickness0low10
Allodynia0low20
Allodynia, Mechanical0low20
Allodynia, Tactile0low20
Allodynia, Thermal0low20
Alzheimer Dementia0low10
Alzheimer Disease0low10
Alzheimer Disease, Early Onset0low10
Alzheimer Disease, Late Onset0low10
Alzheimer Sclerosis0low10
Alzheimer Syndrome0low10
Alzheimer Type Senile Dementia0low10
Alzheimer-Type Dementia (ATD)0low10
Alzheimer's Disease0low10
Alzheimer's Disease, Focal Onset0low10
Alzheimer's Diseases0low10
Anasarca0low10
Anxiety0low40
Anxiety Disorders0low10
Anxiety Neuroses0low10
Anxiety States, Neurotic0low10
Asthma0low10
Asthma, Bronchial0low10
Atonic Absence Seizure0low20
Atonic Absence Seizures0low20
Atonic Seizure0low20
Atonic Seizures0low20
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome0low10
Autism, Dementia, Ataxia, and Loss of Purposeful Hand Use0low10
Benign Infantile Myoclonic Epilepsy0low10
Body Weight0low10
Breast Cancer0low60
Breast Carcinoma0low60
Breast Neoplasms0low60
Breast Tumors0low60
Bronchial Asthma0low10
Cancer of Breast0low60
Cancer of the Breast0low60
Canine Diseases0medium21
Car Sickness0low10
Carcinoma, Cribriform0low10
Carcinoma, Granular Cell0low10
Carcinoma, Tubular0low10
Carsickness0low10
Cerebroatrophic Hyperammonemia0low10
Chronic Airflow Obstruction0low10
Chronic Obstructive Airway Disease0low10
Chronic Obstructive Lung Disease0low10
Chronic Obstructive Pulmonary Disease0low10
Chronic Obstructive Pulmonary Diseases0low10
Clonic Seizure0low20
Clonic Seizures0low20
COAD0low10
Complex Partial Seizure0low20
Complex Partial Seizures0low20
Convulsion0low20
Convulsion, Non-Epileptic0low20
Convulsions0low20
Convulsions, Grand Mal0low10
Convulsive Seizure0low20
Convulsive Seizures0low20
COPD0low10
Coronavirus Disease 20190low20
Coronavirus Disease-190low20
COVID-190low20
COVID-19 Pandemic0low20
COVID-19 Pandemics0low20
COVID-19 Virus Disease0low20
COVID-19 Virus Infection0low20
COVID190low20
Cryptogenic Myoclonic Epilepsy0low10
Cryptogenic Tonic-Clonic Epilepsy0low10
Dementia, Alzheimer Type0low10
Dementia, Presenile0low10
Dementia, Primary Senile Degenerative0low10
Dementia, Senile0low10
Depression, Involutional0low10
Depressive Disorder, Major0low10
Dermatitis, Atopic0medium11
Disease Models, Animal0low60
Dog Diseases0medium21
Doose Syndrome0low10
Dravet Syndrome0low10
Dropsy0low10
Early Childhood Epilepsy, Myoclonic0low10
Early Childhood, Myoclonic Epilepsy0low10
Early Onset Alzheimer Disease0low10
Eczema, Atopic0medium11
Eczema, Infantile0medium11
Edema0low10
Emesis0low40
Encephalopathy, Myoclonic0low10
Epilepsies, Myoclonic0low10
Epilepsy, Early Childhood, Myoclonic0low10
Epilepsy, Grand Mal0low10
Epilepsy, Major0low10
Epilepsy, Myoclonic, Early Childhood0low10
Epilepsy, Myoclonic, Infantile0low10
Epilepsy, Myoclonic, Infantile, Benign0low10
Epilepsy, Myoclonic, Infantile, Severe0low10
Epilepsy, Myoclonus0low10
Epilepsy, Tonic-Clonic0low10
Epilepsy, Tonic-Clonic, Cryptogenic0low10
Epilepsy, Tonic-Clonic, Familial0low10
Epilepsy, Tonic-Clonic, Symptomatic0low10
Epileptic Seizure0low20
Epileptic Seizures0low20
Familial Alzheimer Disease (FAD)0low10
Familial Tonic-Clonic Epilepsy0low10
Focal Onset Alzheimer's Disease0low10
Generalized Absence Seizure0low20
Generalized Absence Seizures0low20
Generalized Tonic-Clonic Seizures0low20
Grand Mal Seizure Disorder0low10
Human Mammary Carcinoma0low60
Hydrops0low10
Hyperalgesia0low20
Hyperalgesia, Mechanical0low20
Hyperalgesia, Primary0low20
Hyperalgesia, Secondary0low20
Hyperalgesia, Tactile0low20
Hyperalgesia, Thermal0low20
Hyperalgesic Sensations0low20
Hyperalgia0low20
Hyperalgia, Mechanical0low20
Hyperalgia, Primary0low20
Hyperalgia, Secondary0low20
Idiopathic Myoclonic Epilepsy0low10
Infantile Severe Myoclonic Epilepsy0low10
Inflammation0low10
Injuries0low10
Injuries and Wounds0low10
Injuries, Wounds0low10
Innate Inflammatory Response0low10
Invasiveness, Neoplasm0low10
Itching0medium11
Jacksonian Seizure0low20
Labhart-Willi Syndrome0low10
Labhart-Willi-Prader-Fanconi Syndrome0low10
Late Onset Alzheimer Disease0low10
Major Depressive Disorder0low10
Major Motor Seizure Disorder0low10
Malignant Neoplasm of Breast0low60
Malignant Tumor of Breast0low60
Mammary Cancer0low60
Mammary Carcinoma, Human0low60
Mammary Neoplasm, Human0low60
Mammary Neoplasms, Human0low60
Mechanical Allodynia0low20
Mechanical Hyperalgesia0low20
Melancholia, Involutional0low10
Memory Deficits0low10
Memory Disorder, Semantic0low10
Memory Disorder, Spatial0low10
Memory Disorders0low10
Memory Disorders, Age-Related0low10
Memory Loss0low10
Metastase0low10
Metastases, Neoplasm0low10
Metastasis0low10
Metastasis, Neoplasm0low10
Motion Sickness0low10
Muscle Contraction0low10
Myoclonic Absence Epilepsy0low10
Myoclonic Astatic Epilepsy0low10
Myoclonic Encephalopathy0low10
Myoclonic Epilepsy0low10
Myoclonic Epilepsy, Benign Infantile0low10
Myoclonic Epilepsy, Early Childhood0low10
Myoclonic Epilepsy, Infantile0low10
Myoclonic Epilepsy, Infantile, Benign0low10
Myoclonic Epilepsy, Infantile, Severe0low10
Myoclonic Epilepsy, Severe Infantile0low10
Myoclonic Epilepsy, Severe, Of Infancy0low10
Myoclonic Seizure0low20
Myoclonic Seizure Disorder0low10
Myoclonic Seizures0low20
Nausea0low100
Neoplasm Invasion0low10
Neoplasm Invasiveness0low10
Neoplasm Metastases0low10
Neoplasm Metastasis0low10
Neoplasms, Breast0low60
Nerve Pain0low10
Neuralgia0low10
Neuralgia, Atypical0low10
Neuralgia, Iliohypogastric Nerve0low10
Neuralgia, Ilioinguinal0low10
Neuralgia, Perineal0low10
Neuralgia, Stump0low10
Neuralgia, Supraorbital0low10
Neuralgia, Vidian0low10
Neurodermatitis, Atopic0medium11
Neurodermatitis, Disseminated0medium11
Neurodynia0low10
Neuropathic Pain0low10
Neuroses, Anxiety0low10
Non-Epileptic Seizure0low20
Non-Epileptic Seizures0low20
Nonepileptic Seizure0low20
Nonepileptic Seizures0low20
Obesity0low10
Pain0low30
Pain, Burning0low30
Pain, Crushing0low30
Pain, Migratory0low30
Pain, Radiating0low30
Pain, Splitting0low30
Paraphrenia, Involutional0low10
Paroxysmal Nerve Pain0low10
Partial Seizure0low20
Partial Seizures0low20
Peripheral Nerve Diseases0low10
Peripheral Nervous System Disease0low10
Peripheral Nervous System Diseases0low10
Peripheral Nervous System Disorders0low10
Peripheral Neuropathies0low10
Petit Mal Convulsion0low20
PNS (Peripheral Nervous System) Diseases0low10
PNS Diseases0low10
Prader Labhart Willi Syndrome0low10
Prader-Labhart-Willi Syndrome0low10
Prader-Willi Syndrome0low10
Presenile Alzheimer Dementia0low10
Primary Senile Degenerative Dementia0low10
Pruritis0medium11
Pruritus0medium11
Psychosis, Involutional0low10
Pulmonary Disease, Chronic Obstructive0low10
Research-Related Injuries0low10
Retention Disorders, Cognitive0low10
Rett Disorder0low10
Rett Syndrome0low10
Rett's Disorder0low10
Rett's Syndrome0low10
Royer Syndrome0low10
Royer's Syndrome0low10
SARS Coronavirus 2 Infection0low20
SARS-CoV-2 Infection0low20
Sea Sickness0low10
Seasickness0low10
Seizure0low20
Seizure Disorder, Grand Mal0low10
Seizure Disorder, Major Motor0low10
Seizure Disorder, Tonic Clonic0low10
Seizures0low20
Seizures, Auditory0low20
Seizures, Clonic0low20
Seizures, Convulsive0low20
Seizures, Epileptic0low20
Seizures, Focal0low20
Seizures, Generalized0low20
Seizures, Gustatory0low20
Seizures, Motor0low20
Seizures, Olfactory0low20
Seizures, Sensory0low20
Seizures, Somatosensory0low20
Seizures, Tonic0low20
Seizures, Tonic-Clonic0low20
Seizures, Vertiginous0low20
Seizures, Vestibular0low20
Seizures, Visual0low20
Semantic Memory Disorder0low10
Senile Dementia, Acute Confusional0low10
Senile Dementia, Alzheimer Type0low10
Sensitivity and Specificity0low10
Severe Infantile Myoclonic Epilepsy0low10
Severe Myoclonic Epilepsy Of Infancy0low10
Severe Myoclonic Epilepsy, Infantile0low10
Single Seizure0low20
Spatial Memory Disorder0low10
Suffering, Physical0low30
Symptomatic Myoclonic Epilepsy0low10
Symptomatic Tonic-Clonic Epilepsy0low10
Tactile Allodynia0low20
Thermal Allodynia0low20
Tonic Clonic Convulsions0low10
Tonic Clonic Seizure0low20
Tonic Seizure0low20
Tonic Seizures0low20
Tonic-Clonic Convulsion Disorder0low10
Tonic-Clonic Convulsion Syndrome0low10
Tonic-Clonic Seizure0low20
Tonic-Clonic Seizure Disorder0low10
Tonic-Clonic Seizure Syndrome0low10
Tonic-Clonic Seizures0low20
Trauma0low10
Tumors, Breast0low60
Vomiting0low40
Weight Loss0low10
Weight Reduction0low10
Willi-Prader Syndrome0low10
Wounds0low10
Wounds and Injuries0low10
Wounds and Injury0low10
Wounds, Injury0low10

Research Highlights

Long-term Use (1)

ArticleYear
A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals.
American journal of veterinary research, May-01, Volume: 84, Issue: 5		2023
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (2)

ArticleYear
A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals.
American journal of veterinary research, May-01, Volume: 84, Issue: 5		2023
Twice-daily oral administration of a cannabidiol and cannabidiolic acid-rich hemp extract was well tolerated in orange-winged Amazon parrots (Amazona amazonica) and has a favorable pharmacokinetic profile.
American journal of veterinary research, Apr-01, Volume: 84, Issue: 4		2023
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (1)

ArticleYear
Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus).
American journal of veterinary research, Aug-13, Volume: 83, Issue: 10		2022
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (5)

ArticleYear
A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals.
American journal of veterinary research, May-01, Volume: 84, Issue: 5		2023
Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus).
American journal of veterinary research, Aug-13, Volume: 83, Issue: 10		2022
The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis.
Veterinary dermatology, Volume: 33, Issue: 4		2022
Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures.
Epilepsy research, Volume: 169		2021
Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa).
Scientific reports, 07-29, Volume: 10, Issue: 1		2020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]